Currently, there are 131.04M common shares owned by the public and among those 130.41M shares have been available to trade.
The company’s stock has a 5-day price change of 2.14% and -1.88% over the past three months. DVAX shares are trading -21.39% year to date (YTD), with the 12-month market performance down to -22.17% lower. It has a 12-month low price of $9.74 and touched a high of $15.15 over the same period. DVAX has an average intraday trading volume of 1.96 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 1.10%, -0.54%, and -6.45% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Dynavax Technologies Corp. (NASDAQ: DVAX) shares accounts for 101.98% of the company’s 131.04M shares outstanding.
It has a market capitalization of $1.44B and a beta (3y monthly) value of 1.35. The stock’s trailing 12-month PE ratio is 100.55, while the earnings-per-share (ttm) stands at $0.11. Price movements for the stock have been influenced by the stock’s volatility, which stands at 2.26% over the week and 2.88% over the month.
Earnings per share for the fiscal year are expected to increase by 485.88%, and 90.96% over the next financial year.
Looking at the support for the DVAX, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on February 01, 2024, with the firm’s price target at $20. JMP Securities coverage for the Dynavax Technologies Corp. (DVAX) stock in a research note released on September 27, 2022 offered a Mkt Outperform rating with a price target of $22. Goldman was of a view on January 06, 2022 that the stock is Buy, while Goldman gave the stock Buy rating on August 06, 2021, issuing a price target of $19. H.C. Wainwright on their part issued Buy rating on August 07, 2020.
